Possibilities of alternative pharmacological approaches to monotherapy for bacterial vaginosis in reproductive-aged patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To present the authors’ own experience with monotherapy for bacterial vaginosis with vaginal gel (Vapigel) in reproductive-aged patients. Materials and methods: The efficiency and compliance of monotherapy for bacterial vaginosis with intravaginal gel (Vapigel) were evaluated in 30 patients on the basis of the time course of changes in clinical symptoms, vaginal fluid pH-metry, the quantitative characteristics of representatives of the vaginal microbiota, and treatment adherence. Results: Vaginal gel (Vapigel) monotherapy for bacterial vaginosis eliminates subjective complaints and clinical symptoms of the disease in 29/30 (96.7%) patients, determines the detection rate for Lactobacillus spp. at a concentration of107 CFU/ml in 26/30(86.6%), and restores the physiological vaginal discharge pH level in 28/30 (93.3%). Adherence to the use of Vapigel was noted in 25/30 (83.3%) patients; no adverse events were observed in 30/30 (100.0%) patients. Conclusion: Clinical efficacy, acceptability, absence of adverse events, and treatment refusals determine the advisability of using Vapigel as a monotherapy for bacterial vaginosis in reproductive-aged women as an important component in the implementation of measures to reduce the prescription of antimicrobial drugs in clinical practice.

Full Text

Restricted Access

About the authors

Elizaveta Yu. Lebedenko

Rostov State Medical University Ministry of Health of the Russian Federation

Email: lebedenko08@mail.ru
Doctor of Medicine, Head of the Department of Obstetrics and Gynecology No. 3 344022, Russia, Rostov-on-Don, per. Nahichevanskiy, 29

Oksana V. Gaida

Rostov State Medical University Ministry of Health of the Russian Federation

Email: gajdaoksana@mail.ru
PhD (Med.), Associate Professor of the Department of Obstetrics and Gynecology 344022, Russia, Rostov-on-Don, per. Nahichevanskiy, 29

Yana V. Mikhailenko

Rostov Regional Clinical Hospital No. 2

Email: yanochka.podina@inboxru
obstetrician-gynecologist of the Gynecological Department 344023, Russia, Rostov-on-Don, 1st Cavalry Army str., 33

Vitaliya G. Anufrieva

Rostov State Medical University Ministry of Health of the Russian Federation

Email: vitaliya@list.ru
obstetrician-gynecologist of the Gynecological Department 344022, Russia, Rostov-on-Don, per. Nahichevanskiy, 29

Mikhail A. Rymashevsky

Rostov State Medical University Ministry of Health of the Russian Federation

Email: mikhail.rymashevskiy@man.ru
assistant of the Department of Obstetrics and Gynecology 344022, Russia, Rostov-on-Don, per. Nahichevanskiy, 29

Natalya V. Sablina

Botkin Hospital Moscow Healthcare Department

Email: natalie_sablina@yahoo.de
obstetrician-gynecologist, Gynecological Department 125284, Russia, Moscow, 2nd Botkinsky pr-d, 5

Angelina V. Bespalaya

Rostov Regional Perinatal Center

Email: angelina-koshka@yandex.ru
оbstetrician-gynecologist of the Maternity Department 344068, Russia, Rostov-on-Don, Bodraya str., 90

References

  1. Глобальная стратегия ВОЗ по сдерживанию устойчивости к противомикробным препаратам [интернет]. Женева: ВОЗ; 2001.
  2. Таточенко В.К. Резистентность к антибиотикам и как ее преодолеть. Комментарий к статье С.В. Ильиной «Нерациональное использование антибиотиков в медицине: кризис антибиотикорезистентности, и что мы можем сделать». Педиатрическая фармакология. 2017; 14(6): 514-9. https://dx.doi.org/10.15690/pf.v14i6.1835.
  3. ВОЗ. Глобальный план действий по борьбе с устойчивостью к противомикробным препаратам [интернет]. Женева: ВОЗ; 2016. Доступно по: http://apps.who.int/iris/bitstream/10665/254884/1/9789244509760-rus.pdf
  4. European Centre for Disease Prevention and Control (ECDC). Last-line antibiotics are failing. 17 Nov 2016. Available at: https://ecdc.europa.eu/en/news-events/last-line-antibiotics-are-failing.
  5. ВОЗ. Устойчивость к антибиотикам. Информационный бюллетень ВОЗ; 2017.
  6. Давыдов Д.С. Национальная стратегия Российской Федерации по предупреждению распространения устойчивости патогенных микроорганизмов к антимикробным препаратам: трудности и перспективы сдерживания одной из глобальных биологических угроз XXI века. БИО препараты. Профилактика, диагностика, лечение. 2018; 18(1): 50-6. https://dx.doi.org/10.30895/2221-996X-2018-18-1-50-56.
  7. Намазова-Баранова Л.С., Баранов А.А. Антибиотикорезистентность в современном мире. Педиатрическая фармакология. 2017; 14(5): 341-54. https://dx.doi.org/10.15690/pf.v14i5.1782.
  8. Ventola C.L. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015; 40(4): 277-83.
  9. Российское общество акушеров-гинекологов. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. 2-е изд. М.: РОАГ; 2019. 56 c.
  10. Кузнецова И.В., Чилова Р.А. Бактериальный вагиноз и вульвовагинальный кандидоз. Акушерство и гинекология. 2018; 5: 143-9. https://dx.doi.org/10.18565/aig.2018.5.143-149.
  11. Радзинский В.Е., Ордиянц И.М. Двухэтапная терапия вагинальных инфекций. М.: StatusPraesens; 2012. 16 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies